Relapse · patients with schizophrenia
INTERMITTENT (GRADUALLY INCREASED DRUG‐FREE PERIODS) may leads to higher relapse: long term (+ 26 weeks) as defined in each study compared with MAINTENANCE THERAPY (low certainty).
1 finding from 1 review
Hospital admissions · patients with schizophrenia
1 finding from 1 review
Global state: average score: long term (+ 26 weeks) Global Assessment Scale (GAS). Scale from: 0 to 100. · patients with schizophrenia
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Adverse effects: tardive dyskinesia: long term (+ 26 weeks) as defined in each study · patients with schizophrenia
1 finding from 1 review
Cost‐effectiveness · patients with schizophrenia
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether INTERMITTENT (GRADUALLY INCREASED DRUG‐FREE PERIODS) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
1 finding from 1 review
Economic: Increased costs of health care · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per NIMH 1987, or with…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Weight gain · patients with schizophrenia
Bromperidol decanoate showed no clear difference in adverse effects ‐ increased weight compared with placebo (low certainty).
1 finding from 1 review
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial · patients with schizophrenia
Paliperidone palmitate showed no clear difference in no clinically important change Number of people whose PANSS score… compared with risperidone long‐acting injection (low certainty).
1 finding from 1 review
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial · patients with schizophrenia
Paliperidone palmitate probably leads to lower no clinically important change Number of people whose PANSS score… compared with placebo (moderate certainty).
1 finding from 1 review